Free Cash Flow

Ligand Pharmaceuticals: Is This Biotech Stock Undervalued? A Deep Dive

Ligand Pharmaceuticals (NASDAQ:LGND) is currently trading at $189, but a recent analysis suggests its true value could be significantly higher. Using a two-stage Discounted Cash Flow (DCF) model, Simply Wall St estimates Ligand’s fair value at $301 per share – a potential 37% upside. But what does this mean for investors, and what factors are driving this valuation gap?

Understanding the DCF Valuation

The DCF model, at its core, attempts to determine a company’s worth based on its expected future cash flows. It’s about figuring out what an investor would be willing to pay today for the money a company will generate in the future. This involves forecasting those cash flows, typically over a 10-year period, and then discounting them back to their present value. The discount rate reflects the risk associated with receiving those future cash flows – the higher the risk, the higher the discount.

Ligand’s valuation utilizes a two-stage approach. The first stage projects higher growth, which gradually stabilizes into a more sustainable ‘steady growth’ period. Analysts project increasing free cash flow (FCF) for Ligand, reaching $316.8 million by 2035. This growth is then discounted back using a 7.0% cost of equity, resulting in a present value of $1.4 billion for the initial 10-year period.

Terminal Value: Looking Beyond the Decade

Beyond the initial 10 years, the DCF model incorporates a ‘terminal value’ – representing the value of the company’s cash flows beyond that timeframe. This is calculated using a conservative growth rate, typically tied to a country’s GDP growth. In Ligand’s case, a 3.3% growth rate (based on the 5-year average of the 10-year government bond yield) is applied. This results in a terminal value of $8.9 billion, with a present value of $4.5 billion.

Combining the present value of the 10-year cash flows and the present value of the terminal value yields an equity value of $5.9 billion. Dividing this by the number of outstanding shares reveals the estimated fair value of $301 per share.

Why the Discrepancy? Analyst Views vs. DCF

Interestingly, the average analyst price target for Ligand is $243, which is 19% lower than the $301 estimate derived from the DCF model. This divergence highlights the subjective nature of valuation. Analysts consider a broader range of factors, including market sentiment, competitor analysis, and potential regulatory hurdles. The DCF model, while rigorous, relies heavily on the accuracy of its inputs.

Pro Tip: Don’t rely on a single valuation method. DCF is a powerful tool, but it’s best used in conjunction with other valuation techniques and a thorough understanding of the company’s business.

Ligand’s Business Model: A Royalty-Focused Approach

Ligand Pharmaceuticals operates a unique royalty-based business model. Instead of directly developing and commercializing drugs, Ligand partners with pharmaceutical companies, providing them with access to its technologies in exchange for royalties on sales. This approach offers several advantages:

• Reduced Risk: Ligand doesn’t bear the full cost and risk of drug development.
• Diversified Revenue: Royalties from multiple drugs and partners create a diversified revenue stream.
• High Margins: Royalties typically have high profit margins.

Recent successes with drugs like Kyprolis (treatment for multiple myeloma) and Promacta (treatment for thrombocytopenia) have contributed to Ligand’s growing cash flows. However, the company is also exposed to risks associated with patent expirations and competition from generic drugs.

Future Trends and Potential Catalysts

Several trends could impact Ligand’s future performance:

• Growth in Bioconjugation Technologies: Ligand’s core technology, Capturx, is a leading bioconjugation platform. Demand for these technologies is expected to grow as more antibody-drug conjugates (ADCs) enter the market.
• Expansion of Royalty Portfolio: Ligand continues to seek new partnerships and licensing agreements to expand its royalty portfolio.
• Innovation in Drug Discovery: Ligand’s internal research and development efforts could lead to the discovery of new drug candidates.

Did you know? Antibody-drug conjugates (ADCs) are a rapidly growing class of cancer therapies that combine the targeting ability of antibodies with the potent killing power of chemotherapy drugs.

Risks to Consider

Despite the positive outlook, investors should be aware of potential risks:

• Patent Expirations: Loss of patent exclusivity for key drugs could significantly reduce royalty revenue.
• Competition: Increased competition in the bioconjugation space could erode Ligand’s market share.
• Reliance on Partners: Ligand’s success depends on the success of its partners.

FAQ

• What is a DCF model? A DCF model estimates a company’s value based on its expected future cash flows.
• What is a terminal value? The terminal value represents the value of a company’s cash flows beyond the initial forecast period.
• Is Ligand Pharmaceuticals a good investment? The DCF model suggests Ligand may be undervalued, but investors should conduct their own due diligence and consider the risks involved.
• What is Ligand’s business model? Ligand operates a royalty-based business model, partnering with pharmaceutical companies and receiving royalties on sales.

Strength: Unique royalty-based business model, diversified revenue stream, high margins.

Weakness: Reliance on partners, exposure to patent expirations.

Opportunity: Growth in bioconjugation technologies, expansion of royalty portfolio.

Threat: Competition, potential regulatory changes.

Ultimately, determining whether Ligand Pharmaceuticals is a worthwhile investment requires a comprehensive analysis of its business, financials, and industry dynamics. The DCF model provides a valuable starting point, but it’s just one piece of the puzzle.

View our latest analysis for Ligand Pharmaceuticals

What are your thoughts on Ligand Pharmaceuticals? Share your insights in the comments below!